Advertisement

DNA Vaccines and Immunity to Herpes Simplex Virus

  • B. T. Rouse
  • S. Nair
  • R. J. D. Rouse
  • Z. Yu
  • N. Kuklin
  • K. Karem
  • E. Manickan
Chapter
Part of the Current Topics in Microbiology and Immunology book series (CT MICROBIOLOGY, volume 226)

Abstract

Infections by herpes simplex virus (HSV) represent an expensive public health problem. Although only rarely a cause of mortality, HSV infections usually cause painful and often distressing lesions and are particularly troublesome since symptomatic recurrent disease is a common outcome once an individual has been infected. Recurrent lesions on the face and genitalia are the most common expression but in some locations, such as the eye, distressing results such as blindness can occur. As regards HSV infections, in 1985 the Committee on Issues and Priorities for New Vaccine Development of the Institute of Medicine set the following goals: a 50% reduction in symptomatic primary infection, a 75% reduction in the number of recurrences and a 60% reduction in the severity of episodes.

Keywords

Herpes Simplex Virus Type Herpes Simplex Virus Infection Intramuscular Immunization High Dose Challenge Herpes Simplex Virus Vaccine 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Arnold D, Faath S, Rammensee HG, Schild H (1995) Cross-priming of minor histocompatibility antigen- specific cytotoxic T cells with the heat shock protein gp96. J Exp Med 182:885–889PubMedCrossRefGoogle Scholar
  2. Bevan MJ (1995) Antigen presentation to cytotoxic T lymphocytes in vivo. J Exp Med 182:639–641PubMedCrossRefGoogle Scholar
  3. Fynan EF, Webster RG, Fuller DH, Haynes JR, Santoro JC, Robinson HL (1993) DNA vaccines: protective immunizations by parenteral, mucosal, and gene-gun inoculations. Proc Natl Acad Sci USA 90:11478–11482PubMedCrossRefGoogle Scholar
  4. Germain RN (1994) MHC-dependent antigen processing and peptide presentation: providing ligands for T lymphocytes activation. Cell 76:287–299PubMedCrossRefGoogle Scholar
  5. Holmgren J, Lycke N, Czerknisky C (1993) Cholera toxin and cholera B subunit as oral mucosal adjuvant and antigen vector systems. Vaccine 11:1179–1184PubMedCrossRefGoogle Scholar
  6. Kovacsovics-Bankowski M, Clark K, Benacerraf B, Rock KL (1993) Efficient major histocompatibility complex class I presentation of exogenous antigen upon phagocytosis by macrophages. Proc Natl Acad Sci USA 90:4942–4946PubMedCrossRefGoogle Scholar
  7. Kriesel JD, Spruance SL, Daynes RA, Araneo B (1996) Nucleic acid vaccine encoding glycoprotein D2 protects mice from herpes simplex virus type 2 disease. J Infect Dis, In pressGoogle Scholar
  8. Kuklin N, Daheshia M, Karem K, Manickan E, Rouse BT (1997) Induction of mucosal immunity against herpes simplex virus by plasmid DNA immunization. J Virol 71:3138–3145PubMedGoogle Scholar
  9. Kutinova L, Benda R, Kalos Z (1988) Placebo-controlled study with subunit herpes simplex virus vaccine in subjects suffering form frequent herpetic recurrences. Vaccine 6:223–228PubMedCrossRefGoogle Scholar
  10. Manickan E, Francotte M, Kuklin N, Dewerchin M, Molito C, Gheysen D, Slaoui M, Rouse BT (1995a) Vaccination with recombinant vaccinia viruses expressing ICP27 induces protective immunity against herpes simplex virus though CD4+ Thl + T cells. J Virol 69:4711–4716PubMedGoogle Scholar
  11. Manickan E, Rouse RJD, Yu Z, Wire WS, Rouse BT (1995b) Genetic immunization against herpes simplex virus protection is mediated by CD4 T lymphocytes. J Immunol 155:259–265PubMedGoogle Scholar
  12. Manickan E, Yu Z, Rouse RJD, Wire WS, Rouse BT (1995c) Induction of protective immunity against herpes simplex virus with DNA encoding the immediate early protein ICP27. Viral Immunol 8:53–61PubMedCrossRefGoogle Scholar
  13. Mester JC, Rouse BT (1991) The mouse model and understanding immunity to herpes simplex virus. Rev Infect Dis 13:S935–945PubMedCrossRefGoogle Scholar
  14. Mossmann TR, Cherwinski H, Bond MW, Giedlin MA, Coffman RL (1986) Two types of murine helper T cell clones. J Immunol 136:2348–2357Google Scholar
  15. Nair S, Rouse RJD, Bruce BD, Rouse BT (1996) Interaction between macrophages and dendritic cells involves a putative peptide chaperon. SubmittedGoogle Scholar
  16. Nair S, Zhou F, Huang L, Rouse BT (1992a) Class I restricted CTL recognition of a soluble protein delivered by liposomes containing lipophilic polylysines. J Immunol Methods 152:237–243PubMedCrossRefGoogle Scholar
  17. Nair S, Zhou F, Reddy R, Huang L, Rouse BT (1992b) Soluble proteins delivered to dendritic cells via pH-sensitive liposome induce primary cytotoxic T lymphocyte response in vitro. J Exp Med 175:609–612PubMedCrossRefGoogle Scholar
  18. Nguyen L, Knipe DM, Finberg RW (1994) Mechanisms of virus-induced Ig subclass shifts. J Immunol 152:478–484PubMedGoogle Scholar
  19. Pfeifer JD, Wick MJ, Roberts RL, Findley K, Normark SJ, Harding CV (1993) Phagocytic processing of bacterial antigens for class I MHC presentation to T cells. Nature 361:153–177CrossRefGoogle Scholar
  20. Rouse RJD, Nair SK, Lydy SL, Bowen JC, Rouse BT (1994) Induction in vitro of primary cytotoxic T-lymphocyte responses with DNA encoding herpes simplex virus proteins. J Virol 68:5685–5689PubMedGoogle Scholar
  21. Simmons A, Nash AA (1984) Zosteriform spread of herpes simplex virus as a model of recrudescence and its use to investigate the role of immune cells in prevention of recurrent diseases. J Virol 53:128–136Google Scholar
  22. Simmons A, Tscharke DC (1992) Anti-CD8 impairs clearance of herpes simplex virus from the nervous system: implications for the fate of virally infected neurons. J Exp Med 175:1337–1344PubMedCrossRefGoogle Scholar
  23. Srivastava PK (1993) Peptide-binding heat shock protein in the endoplasmic reticulum: role in immune response to cancer and in antigen presentation. Adv Cancer Res 62:153–177PubMedCrossRefGoogle Scholar
  24. Stanberry LR (1996) Herpes immunization - on the threshold. J Eueop Acad Dermatol Venerol 7:120–128Google Scholar
  25. Straus SE, Corey L, Burke RL, Savarese B, Barnum G, Krause PR, Kost RG, Meier JL, Sekulovich R, Adair SF (1984) Placebo-controlled trial of vaccination with recombinant glycoprotein D of herpes simplex virus type 2 for immunotherapy of genital herpes. Lancet 343:1460–1463CrossRefGoogle Scholar
  26. Witmer-Pack MD, Oliver W, Valinsky J, Schuler G, Steinman RM (1987) Granulocyte/macrophage colony-stimulating factor is essential for the viability and function of cultured murine epidermal Langerhans cells. J Exp Med 166:1484–1498PubMedCrossRefGoogle Scholar
  27. Wolff TA, Malone RW, Williams P, Chong W, Acsadi G, Jani A, Feigner PL (1990) Direct gene transfer into mouse muscle in vivo. Science 247:1465–1468PubMedCrossRefGoogle Scholar
  28. Xiang Z, Ertl HCJ (1995) Manipulation of the immune response to a plasmid-encoded viral antigen by coinoculation with plasmid expressing cytokines. Immunity 2:129–135PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1998

Authors and Affiliations

  • B. T. Rouse
    • 1
  • S. Nair
    • 2
  • R. J. D. Rouse
    • 1
  • Z. Yu
    • 1
  • N. Kuklin
    • 1
  • K. Karem
    • 1
  • E. Manickan
    • 1
  1. 1.Department of MicrobiologyUniversity of TennesseeKnoxvilleUSA
  2. 2.Department of SurgeryDuke University Medical CenterDurhamUSA

Personalised recommendations